Edition:
United Kingdom

People: Biospecifics Technologies Corp (BSTC.OQ)

BSTC.OQ on NASDAQ Stock Exchange Global Market

61.02USD
7:50pm BST
Change (% chg)

$-1.38 (-2.21%)
Prev Close
$62.40
Open
$62.36
Day's High
$62.68
Day's Low
$60.86
Volume
8,440
Avg. Vol
17,524
52-wk High
$73.31
52-wk Low
$43.50

Mattila, Jyrki 

Dr. Jyrki Mattila, M.D. Ph.D. is an Independent Director of the Company. Dr. Jyrki Mattila has served as Chief Business Officer at iCeutica Inc. since October 2013. Prior to joining iCeutica, from 2010 to 2013, Dr. Mattila served as President and CEO of LZ Therapeutics, Inc. Before that, he was Executive Vice President of Business Development, Product Development and Technical Operations at Auxilium Pharmaceuticals, Inc. Dr. Mattila previously served in a series of positions with increasing seniority at Orion Corporation, including as President of Orion Pharma, where under his leadership several innovative products were developed and commercialized in global markets. He has negotiated and closed over 50 business agreements, including licensing, co-marketing, collaboration and product acquisition arrangements. Dr. Mattila received his M.D. and a Ph.D. in Pharmacology from the University of Helsinki Medical School and his M.B.A. from the Helsinki School of Economics. Dr. Mattila completed his post-doctoral research fellowship at the University of Kansas Medical Center.

Basic Compensation

Total Annual Compensation, USD 75,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 270,150
Fiscal Year Total, USD 345,150

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ronald Law

375,000

Patrick Caldwell

--

Mark Wegman

50,000

Toby Wegman

22,000

Jennifer Chao

340,150

Paul Gitman

45,000
As Of  31 Dec 2018